Anti-ANAPC2 antibody for sale

LS-C356339 is an unconjugated rabbit polyclonal antibody to human ANAPC2. Validated for IHC, Peptide-ELISA and WB. Recognizes endogenous protein. It has been shown to detect ANAPC2 in mouse, rat, zebrafish and human tissues. More info bosterbio.com

The advent of highly targeted monoclonal antibodies (mAbs) in the clinic has led to advances in therapeutic applications spanning many indications, including immune-mediated inflammatory diseases, infectious diseases, and oncology [1]. However, these advances are often limited by large-scale bioprocessing challenges that may impede large-scale manufacturing of these potent agents as well as limitations in their delivery to the target site of action.

ANAPC2 Antibody for Sale: Top Sources and Pricing

Specifically, high doses of mAbs must be administered via intravenous (IV) injection to achieve effective therapeutic outcomes and limit infusion reactions. This imposes significant logistical and operational challenges for patients, requiring extensive clinical monitoring by medical professionals during the infusion process and afterward. Moreover, IV administration is invasive and requires access to reliable health care facilities. In addition, most mAbs require lengthy drug development and clinical trials prior to receiving FDA approval (e.g., palivizumab (Synagis) for prevention of respiratory syncytial virus infection) [2].

These limitations have resulted in several recently approved mAbs being administered through subcutaneous (SC) delivery, such as raxibacumab (Zinplava) for treatment of Clostridium difficile infection and obiltoxaximab (Fabricade) for inhalational anthrax protection under the FDA Animal Efficacy Rule. Subcutaneous delivery has been associated with reduced toxicity, clinical time, and costs for patients receiving these lifesaving treatments.